Intersect Capital LLC quarter change: Foreign ADRs, Unchanged
In depositary receipts for foreign shares (depositary receipts and foreign shares traded over the counter), from the quarter ended 2016-06-30 to 2016-09-30, Intersect Capital LLC opened 1 positions, added to 1, reduced 0, sold out of 0 and left 0 unchanged. The largest increase in value was Glaxosmithkline Plc Adrf (+$226,000); the largest decrease was Royal Dutch Shell B Adrf (-$5,000).
Two Form 13F-HR filings compared (SEC CIK 1633861): 2016-06-30 (filed 2016-08-09) and 2016-09-30 (filed 2016-10-27). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move; share change is the position change.
No position of this class changed this way between the two filings.
Similar Firms
| Firm Name | Country | 13F Value | Holdings |
|---|---|---|---|
| Not available yet | |||